GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release by activating the ghrelin receptor — the original clinically studied GHRP, now mostly used where appetite stimulation is a specific goal.
What it does
GHRP-6 binds the GHS-R1a receptor (the growth hormone secretagogue receptor), which triggers a calcium-dependent process inside pituitary cells that releases stored growth hormone into the bloodstream Xiaotong 2025. This is the same core pathway shared by ipamorelin and GHRP-2, but GHRP-6 is considerably less selective — meaning it activates more off-target receptors alongside GH release.
That lack of selectivity has two notable consequences. First, GHRP-6 raises cortisol and prolactin more than any other major GHRP. Second, GHS-R1a activation in the gut and hypothalamic arcuate nucleus (the brain's appetite control center) produces pronounced hunger — typically starting 15–30 minutes after injection Jázmin 2025. For someone in a catabolic state or with appetite loss, that's a feature; for someone watching caloric intake, it's a problem.
There is also evidence of cardioprotective effects through GHS-R1a receptors in cardiac tissue. One 2024 study found GHRP-6 prevented myocardial and extra-myocardial damage caused by doxorubicin (a chemotherapy drug) by activating cell-survival pathways Jorge 2024. This line of research parallels work on hexarelin but is less developed.
What the evidence shows
Growth hormone secretion Strong rodent and in-vitro evidence; modest human pharmacokinetic data
GHRP-6 reliably increases GH pulse amplitude via GHS-R1a activation. A validated analytical method confirmed dose-dependent GHRP-6 levels in biological matrices, supporting its pharmacokinetic profile across routes including transdermal formulations L 2021. The GH release mechanism is well-characterized, though long-term human outcome data — muscle mass, body composition, aging endpoints — remain thin.
Appetite stimulation and cachexia Mechanistically well-supported; rodent studies strong; human cachexia data limited
The appetite-stimulating effect is one of GHRP-6's most reproducible properties, mediated directly through ghrelin receptor activation in the gut and hypothalamus Jázmin 2025. This makes it a logical candidate for conditions involving involuntary weight loss or appetite suppression, including cancer cachexia (muscle and weight wasting from illness). A 28-day subchronic safety study of a related GHRP compound (CIGB-500) in beagle dogs found an acceptable safety profile at repeated daily doses Jorge 2025, but controlled human cachexia trials with GHRP-6 specifically are lacking.
Cardioprotection Rodent and cell-culture evidence; no human trials
In a 2024 study, GHRP-6 prevented doxorubicin-induced cardiac and systemic damage by activating prosurvival signaling pathways via cardiac GHS-R1a receptors Jorge 2024. Ghrelin itself has shown anti-inflammatory and anti-fibrotic effects in other organ systems, including modulating immune responses in parasitic liver infections Jiang 2024 and reducing inflammatory markers in pancreatic tissue under metabolic stress Xin-Ying 2024. These findings suggest a broader cytoprotective profile, but none of it has been tested in human cardiovascular trials.
Tissue repair and organ protection Early-stage rodent and in-vitro evidence only
A 2025 study demonstrated that a GHRP-6-loaded hydrogel reduced acute kidney injury in rodents by modulating metabolic pathways Xiaotong 2025. Separately, receptor-modulating compounds structurally related to GHRP-6 are being studied for CD36 receptor activity Xiaozheng 2025, which is involved in lipid metabolism and inflammation. Both are interesting mechanistic leads — neither has human trial data.
Nicotine withdrawal / neurological Single rodent study; preliminary
One 2025 rat study found that GHRP-6 and ghrelin attenuated changes in locomotor activity during acute nicotine withdrawal Jázmin 2025. The ghrelin system's role in reward circuitry makes this biologically plausible, but this is a single preclinical study and a long way from a clinical application.
How it's used
In studies and self-reported protocols, doses range from 100 mcg subcutaneously twice daily at the low end, to 100–200 mcg three times daily for moderate use, to 300 mcg three times daily at the high end. The half-life is approximately 50 minutes L 2021, so multiple daily injections are used to generate repeated GH pulses. Timing is typically pre-meal and at bedtime — the pre-meal window aligns with the expected hunger spike and provides a food buffer; the bedtime dose aims to amplify the natural overnight GH pulse. Subcutaneous (under the skin) injection is the standard route. Transdermal formulations have been studied analytically L 2021 but are not a common self-administration route.
Side effects and safety
The most consistent side effect is intense hunger within 15–30 minutes of injection — more pronounced than with any other major GHRP Jázmin 2025. Water retention, flushing, and mild dizziness are also commonly reported. At moderate-to-high doses, elevated cortisol and elevated prolactin (a hormone that can affect mood, libido, and reproductive function) are documented concerns — more so than with GHRP-2 or ipamorelin. Joint pain and headache have been reported. CIGB-500, a related GHRP, showed acceptable tolerability in a 28-day dog study Jorge 2025, but long-term safety in humans is not established. Because GH secretagogues can theoretically accelerate the growth of pre-existing tumors, active malignancy is an absolute contraindication. Diabetes and cortisol-sensitive conditions (e.g., anxiety disorders, Cushing's-adjacent states) warrant extra caution given the cortisol elevation. Long-term effects on pituitary function, insulin sensitivity, and cardiovascular markers in humans are essentially unknown.
Bottom line
GHRP-6 is a well-characterized GH secretagogue with the least clean hormonal profile of the major GHRPs — it works, but it brings cortisol elevation, prolactin elevation, and pronounced appetite stimulation along for the ride. The human evidence base for performance or longevity outcomes is thin; most of the interesting data comes from rodent models. It makes the most sense in contexts where appetite stimulation is specifically wanted; for pure GH release with fewer side effects, ipamorelin or GHRP-2 are the more selective alternatives.